Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome (RE-KLAIM)

Corcept Therapeutics logo

Corcept Therapeutics

Status

Completed

Conditions

Cushing's Syndrome

Treatments

Other: No intervention

Study type

Observational

Funder types

Industry

Identifiers

NCT02663609
C1073-450

Details and patient eligibility

About

Chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome.

Full description

A retrospective, multi-center, chart review study to collect patient data from medical charts of patients who have been treated with Korlym® for the treatment of ACTH independent adrenal Cushing's Syndrome. Treatment with Korlym® will be a minimum 3 months in duration with follow-up of a minimum 3 months. Only sites that have been identified to have patients appropriate for this protocol will be invited to participate.

Enrollment

24 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosed with ACTH independent endogenous Cushing's Syndrome
  • Available adrenal imaging prior to being treated with Korlym®
  • Treated with Korlym® and followed for at least 3 months (follow-up data should be available)

Exclusion criteria

  • Diagnosed with adrenocortical carcinoma
  • Participant in any clinical trial(s) during the observational period

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems